Benitec Biopharma (BNTC) Revenue (2019 - 2023)

Benitec Biopharma (BNTC) has 5 years of Revenue data on file, last reported at $7000.0 in Q2 2023.

• For the quarter ending Q2 2023, Revenue changed N/A year-over-year to $7000.0; the trailing twelve-month figure through Mar 2024 stood at $7000.0 (down 89.71% YoY), and the FY2023 full-year result was $75000.0, up 2.74% from the prior year.
• Revenue fell to $7000.0 in Q2 2023, from $54000.0 in the prior quarter.
• In the past five years, Revenue ranged from a high of $77000.0 in Q4 2019 to a low of -$35000.0 in Q2 2020.
• A 5-year average of $23846.2 and a median of $25000.0 in 2021 frame the typical range for Revenue.
• Across the five-year window, Revenue sank 98.7% in 2020 and soared 4700.0% in 2022, its largest moves.
• Tracing BNTC's Revenue over 5 years: stood at $77000.0 in 2019, then slumped by 98.7% to $1000.0 in 2020, then jumped by 2400.0% to $25000.0 in 2021, then tumbled by 44.0% to $14000.0 in 2022, then tumbled by 50.0% to $7000.0 in 2023.
• Business Quant data shows BNTC's Revenue at $7000.0 in Q2 2023, $54000.0 in Q1 2023, and $14000.0 in Q4 2022.